Silence Therapeutics plc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SLNCF Over the counter 8731 https://www.silence-therapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Silence Therapeutics plc

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences - Aug 27th, 2024 12:00 pm
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Aug 18th, 2024 1:15 pm
Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations - Aug 17th, 2024 12:27 pm
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Aug 15th, 2024 11:30 am
The 3 Best Gene Editing Stocks to Buy in August 2024 - Aug 7th, 2024 1:00 pm
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks - Jul 25th, 2024 10:08 am
Institutional investors are Silence Therapeutics plc's (NASDAQ:SLN) biggest bettors and were rewarded after last week's US$76m market cap gain - Jul 15th, 2024 10:32 am
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Jul 12th, 2024 2:09 pm
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients - Jun 27th, 2024 11:30 am
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration - Jun 24th, 2024 12:30 pm
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) - Jun 20th, 2024 11:30 am
One Silence Therapeutics Insider Raised Their Stake In The Previous Year - Jun 17th, 2024 4:16 pm
Silence Therapeutics to Present at Jefferies Global Healthcare Conference - May 30th, 2024 12:30 pm
Silence Therapeutics (NASDAQ:SLN) Is In A Good Position To Deliver On Growth Plans - May 21st, 2024 3:59 pm
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress - May 16th, 2024 12:30 pm
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference - Apr 30th, 2024 12:30 pm
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors - Apr 29th, 2024 12:30 pm
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Apr 12th, 2024 12:21 pm
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 - Apr 11th, 2024 4:24 pm
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) - Apr 8th, 2024 3:48 pm